Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 4, 2013

4SC Discovery, Crelux, and AiCuris Collaborate on Drug Discovery for Infectious Diseases

  • 4SC Discovery and Crelux have entered a collaboration with AiCuris to identify and validate novel small molecule compounds targeting pathogen-specific interactions in infectious diseases.

    Based on the joint integrated drug discovery platform i2c ("idea-to-candidate") operated by 4SC Discovery and Crelux, the two companies will discover and optimize small molecule compounds with the goal to deliver high-quality drug candidates for an anti-infectious therapeutic approach by AiCuris.

    Using 4SC's 4SCan® method, a virtual screening approach will be performed to identify various inhibitors to the therapeutic target. Compounds identified as potential inhibitors of the respective target will be verified by using both established assays at AiCuris and the Intract in vitro screening systems at Crelux, the company said. In the course of the further discovery process, protein structures of verified hits with the target will be solved by i2c to enable rational design and guide further chemical optimization.

    According to 4SC, the i2c platform operates on an integrated suite of technologies including virtual high-throughput screening, molecular modeling, X-ray crystallography, in vitro and cell-based screening, medicinal chemistry, and pharmacology.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »